Home » Stocks » G1 Therapeutics

G1 Therapeutics, Inc. (GTHX)

Stock Price: $20.39 USD -0.96 (-4.50%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Pre-market: $20.36 -0.03 (-0.15%) Jul 10, 6:36 PM

Stock Price Chart

Key Info

Market Cap 769.46M
Revenue (ttm) n/a
Net Income (ttm) -129.52M
Shares Out 37.74M
EPS (ttm) -3.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $20.39
Previous Close $21.35
Change ($) -0.96
Change (%) -4.50%
Day's Open 21.31
Day's Range 20.29 - 21.73
Day's Volume 536,201
52-Week Range 8.80 - 41.80

More Stats

Market Cap 769.46M
Enterprise Value 535.18M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.74M
Float 28.63M
EPS (basic) -3.45
EPS (diluted) -3.45
FCF / Share -2.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.15M
Short Ratio 4.98
Short % of Float 13.33%
Beta 2.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.51
Revenue n/a
Operating Income -134.98M
Net Income -129.52M
Free Cash Flow -107.55M
Net Cash 234.29M
Net Cash / Share 6.21
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.74%
ROE -45.57%
ROIC -14,870.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(180.97% upside)
Current: 20.39
Target: 57.29
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit----0.52
Operating Income-129-89.29-60.97-30.39-15.42
Net Income-122-85.29-60.12-30.29-20.26
Shares Outstanding37.5033.3218.201.491.34
Earnings Per Share-3.27-2.56-3.57-23.33-16.13
Operating Cash Flow-99.57-74.31-50.52-25.14-13.85
Capital Expenditures-2.72-0.71-0.29-0.25-0.09
Free Cash Flow-102-75.02-50.81-25.39-13.93
Cash & Equivalents27036910447.3122.94
Total Debt9.54----
Net Cash / Debt26036910447.3122.94
Book Value25635993.39-64.99-31.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name G1 Therapeutics, Inc.
Country United States
Employees 104
CEO Mark A. Velleca

Stock Information

Ticker Symbol GTHX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GTHX
IPO Date May 17, 2017


G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.